RESUMO
BACKGROUND: Proton pump inhibitors (PPIs) facilitate intestinal bacterial translocation. No robust data exist demonstrating that PPIs increase the risk of spontaneous bacterial peritonitis (SBP) and that PPIs worsen the prognosis of SBP patients. PPI use might be unsuitable for cirrhotic patients. AIMS: To analyse: (i) the role of PPIs in the occurrence of SBP in cirrhotic patients; (ii) their impact on the prognosis of SBP patients; and (iii) the suitability of their use. METHODS: In this retrospective case-control study, PPI use was first assessed in cirrhotic patients consecutively admitted with SBP (group I) and in a control group that included the same number of uninfected cirrhotic patients with ascites (group II). Afterwards, the impact of PPIs on SBP was assessed in group I by comparing survival of patients with and without PPIs. RESULTS: A total of 102 patients were included, 51 in each group. (i) SBP patients were more frequently treated by PPIs than controls (49 vs. 25%, P = 0.014). (ii) In group I, patients with (n = 25) and without (n = 26) PPIs had similar survival rates at 1 month (64.0 ± 9.6% vs. 59.4 ± 10.0%), 3 months (41.2 ± 10.2% vs. 44.6 ± 10.6%), and 1 year (26.6 ± 9.6% vs. 28.9 ± 10.1%), and similar median age at death (53 vs. 57 years). (iii) The reason for PPI use was inappropriate or undocumented in 34% of group I and II. CONCLUSIONS: Proton pump inhibitors were more frequently used in SBP patients than in controls, but did not influence the prognosis in SBP. Overuse of PPIs was encountered in one-third of cirrhotic patients and should be avoided.
Assuntos
Ascite/complicações , Translocação Bacteriana/efeitos dos fármacos , Cirrose Hepática/complicações , Peritonite/etiologia , Inibidores da Bomba de Prótons/efeitos adversos , Ascite/microbiologia , Estudos de Casos e Controles , Humanos , Estimativa de Kaplan-Meier , Cirrose Hepática/microbiologia , Estudos Retrospectivos , Estatísticas não ParamétricasRESUMO
Increasing evidence accumulates for a role of environmental factors in the onset of inflammatory bowel diseases (IBD). Among them, factors that might disturb the gut microflora hold an important place. As such, antibiotics deserve a special attention, and a possible association between their use, particularly during childhood, and the development of IBD, has been assessed by several authors since 1987. Results, conclusions, and possible impact of their observations, as well as perspectives for the future, are discussed here, in view of the article published in this issue of the Journal by Shaw et al.
Assuntos
Antibacterianos/efeitos adversos , Doenças Inflamatórias Intestinais/induzido quimicamente , Antibacterianos/administração & dosagem , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Doenças Inflamatórias Intestinais/epidemiologia , Intestinos/microbiologia , Masculino , Fatores de RiscoRESUMO
INTRODUCTION: Nationwide studies comparing patients with hepatitis B and C virus (HBV and HCV) infections are mandatory for assessing changes in epidemiology. AIM: The aim of this study was to compare epidemiological data and initial management of newly diagnosed patients with persistent HBV (HBsAg positive) or HCV (detectable HCV RNA) infection in Belgium. PATIENTS AND METHODS: Data were extracted from two Belgian observational databases. RESULTS: A total of 655 patients (387 HBV and 268 HCV) were included. Compared with HCV patients, HBV patients were younger, more frequently men, more often of Asian or African origin (43 vs. 10%, P<0.0001), and less frequently contaminated by transfusion or intravenous drug use (9 and 6% vs. 34 and 44%, P<0.0001). Viral replication was assessed in 89% of HBV patients. Compared with HCV patients, HBV patients more frequently had normal alanine aminotransferase (ALT) levels (65 vs. 29%, P<0.0001), less frequently underwent liver biopsy (29 vs. 67%, P<0.0001), and were less often considered for antiviral therapy (25 vs. 54%, P<0.0001). When taking only HBV patients with detectable viral replication into consideration, results remained unchanged. During the multivariate analysis, ALT was a major factor for performing liver biopsy or considering antiviral therapy in both groups. CONCLUSION: HBV and HCV screening policies should be targeted toward immigrants and intravenous drug users, respectively. Guidelines recommending systematic search for viral replication should be reinforced in HBV patients. HBV patients less frequently underwent liver biopsy and were less often considered for antiviral therapy compared with HCV patients. Despite the lack of sensitivity and specificity, ALT remains a pivotal decision-making tool for liver biopsy and antiviral therapy in both infections.
Assuntos
Hepatite B/epidemiologia , Hepatite C/epidemiologia , Adulto , Fatores Etários , Alanina Transaminase/sangue , Antivirais/uso terapêutico , Bélgica/epidemiologia , Biomarcadores/sangue , Biópsia , Portador Sadio/epidemiologia , Epidemias , Feminino , Hepatite B/diagnóstico , Hepatite B/tratamento farmacológico , Hepatite B/transmissão , Antígenos de Superfície da Hepatite B/sangue , Vírus da Hepatite B/fisiologia , Hepatite C/diagnóstico , Hepatite C/tratamento farmacológico , Hepatite C/transmissão , Humanos , Fígado/patologia , Masculino , Pessoa de Meia-Idade , Sistema de Registros , Fatores de Risco , Fatores Sexuais , Carga Viral , Replicação ViralRESUMO
The management of IBD remains a challenge, with the main issue being to combine therapeutic efficiency with minimal side effects and optimal quality of life. Efforts towards achieving this objective continued in 2010we discuss some of the most relevant publications and their potential impact on daily practice in the future.
Assuntos
Fármacos Gastrointestinais/efeitos adversos , Doenças Inflamatórias Intestinais/tratamento farmacológico , Qualidade de Vida , Anticorpos Monoclonais/efeitos adversos , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais Humanizados , Azatioprina/efeitos adversos , Azatioprina/uso terapêutico , Fármacos Gastrointestinais/uso terapêutico , Humanos , Infliximab , Fatores de Risco , Tromboembolia/epidemiologiaRESUMO
We present here two siblings with a history of recurrent oral and genital ulcers, neurological and gastrointestinal manifestations. The diagnosis of Behçet's disease in a context of familial aggregation was assumed. Facing repeated steroid-dependent flares and failure of maintenance therapies with colchicine and intolerance to pentoxifilline and disulone, adalimumab was started. Rapid response was observed in both patients, with clinical remission after induction therapy, which currently sustains under maintenance schedule. This case report suggests the effectiveness of adalimumab as first anti-TNFα in case of steroid-dependent/resistant gastrointestinal BD.
Assuntos
Anti-Inflamatórios/uso terapêutico , Anticorpos Monoclonais Humanizados/uso terapêutico , Síndrome de Behçet/tratamento farmacológico , Gastroenteropatias/tratamento farmacológico , Adalimumab , Adolescente , Síndrome de Behçet/diagnóstico , Doença de Crohn/diagnóstico , Diagnóstico Diferencial , Feminino , Gastroenteropatias/diagnóstico , Humanos , Adulto JovemRESUMO
We report two cases of Stevens-Johnson syndrome (SJS) associated with the use of sulfasalazine in two ulcerative colitis patients previously tolerant to mesalamine. SJS and toxic epidermal necrolysis (TEN) are very rare adverse cutaneous reactions that can be associated with the use of sulfasalazine. The most severe cases can result in death, and for the others, permanent skin, mucosal or ocular sequelae, which can impair the quality of life in our young IBD patients. Clinicians and patients need to be aware of the signs and symptoms that often precede the appearance of the mucocutaneous lesions in a SJS or TEN, such as fever, influenza-like symptoms, sore throat or burning eyes. For patients with SJS or TEN, immediate withdrawal of the offending medication should be done when blisters or erosions appear in the course of a drug eruption, as this may improve the prognosis.
Assuntos
Anti-Inflamatórios não Esteroides/efeitos adversos , Colite Ulcerativa/tratamento farmacológico , Síndrome de Stevens-Johnson/etiologia , Sulfassalazina/efeitos adversos , Adulto , Feminino , Humanos , Síndrome de Stevens-Johnson/diagnósticoRESUMO
BACKGROUND: A 33-year-old female presented with a history of recurrent epigastric pain and vomiting of bile, accompanied by duodenal wall thickening seen on an abdominal CT scan and a congestive, bluish and ischemic-looking duodenal mucosa as visualized by endoscopy. The patient's medical history was notable for paroxysmal nocturnal hemoglobinuria diagnosed 15 years before. The patient was usually treated with danazol and warfarin and she received regular blood transfusions for hemolytic anemia. INVESTIGATIONS: Medical history and physical examination. Blood tests, coagulation study, search for thrombophilic disorders and small vessel vasculitis. Stool culture and virology. Test for autoantibodies. Abdominal CT scan. Upper gastrointestinal endoscopy with duodenal biopsies. DIAGNOSIS: Small bowel ischemia complicating paroxysmal nocturnal hemoglobinuria. MANAGEMENT: Treatment with warfarin was started but ischemic episodes recurred despite appropriate anticoagulation. Treatment with the complement inhibitor eculizumab was then proposed.